Streetbeat News

TCBP

TC Biopharm (Holdings) Plc

https://www.tcbiopharm.com

Industry

Biotechnology

TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an unmodified cell therapy used in the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat COVID-19. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.

Open

0.78

Mkt cap

188K

Volume

27M

High

0.96

P/E Ratio

N/A

52-wk high

138.00

Low

0.56

Div yield

N/A

52-wk low

0.56

Fangdd Network Group Ltd. (NASDAQ:DUO) shares surged 78.3% in pre-market trading after announcing its 2024 strategic plan to enter the real estate stock asset services sector. Other stocks showed significant movement in pre-market trading, with Kidpik Corp. (NASDAQ:PIK) and Auddia Inc. (NASDAQ:AUUD) among the top gainers, while Semilux International Ltd. (NASDAQ:SELX) and Lytus Technologies Holdings PTV. Ltd. (NASDAQ:LYT) led the losers.

Portfolio Pulse from Avi Kapoor

March 11, 2024 | 12:08 pm

In Wednesday's intraday session, several healthcare stocks experienced significant movements. Aptorum Gr (APM) led the gainers with a 780.6% increase, while bioAffinity Technologies (BIAF) headed the losers with a 45% decrease. Other notable movers included NKGen Biotech (NKGN), Trxade Health (MEDS), and Vincerx Pharma (VINC) among the gainers, and Heart Test Laboratories (HSCS), Ocean Biomedical (OCEA), and TC BioPharm (Holdings) (TCBP) among the losers.

Portfolio Pulse from Benzinga Insights

March 06, 2024 | 5:31 pm

TCBP announced that the MHRA has accepted an amendment for the ACHIEVE UK trial, which includes increasing the dose level to align with Cohort 2 in the IND and changing the procedure from 'in patient' to 'out patient'.

Portfolio Pulse from Benzinga Newsdesk

February 22, 2024 | 2:35 pm

TC BioPharm (Holdings) PLC (NASDAQ:TCBP), a clinical stage biotechnology company, announced significant operational achievements including FDA clearance for a Phase 1B study in AML, a new collaboration with Queen Mary University of London, and cost-savings of approximately $11.6M. The company successfully dosed the final patient in the ACHIEVE Study safety cohort and looks forward to interim data in 2024. TCBP also highlighted its focus on strategic partnerships and platform expansion into anti-fungal and anti-bacterial programs.

Portfolio Pulse from Benzinga Newsdesk

February 14, 2024 | 1:46 pm

Health care stocks experienced significant movements in Monday's intraday session. Renalytix saw a dramatic increase of 490.4%, while AN2 Therapeutics faced a sharp decline of 75%. Other notable movers include Regencell Bioscience and Genenta Science with substantial gains, and InVivo Therapeutics and TC BioPharm with significant losses.

Portfolio Pulse from Benzinga Insights

February 12, 2024 | 5:31 pm

In Monday's pre-market session, several healthcare stocks showed significant movement. SeaStar Medical Holding (ICU) led the gainers with a 27.9% increase, while AN2 Therapeutics (ANTX) experienced the largest drop among the losers, declining by 69%. Other notable movers included Aesthetic Medical Intl (AIH), Virios Therapeutics (VIRI), and Exscientia (EXAI) with substantial gains, and Larimar Therapeutics (LRMR) and Invivyd (IVVD) with notable losses.

Portfolio Pulse from Benzinga Insights

February 12, 2024 | 1:06 pm

Take-Two Interactive Software, Inc. (TTWO) shares fell by approximately 9% following disappointing third-quarter results and a downward revision of its 2024 net bookings forecast. Other stocks experienced significant movements, with Sunworks, Inc. (SUNW) filing for Chapter 7 bankruptcy, leading to a 267% jump in its shares. Masonite International Corporation (DOOR) surged 34.5% after Owens Corning announced its acquisition for $3.9 billion. Various companies reported financial results, leading to both gains and losses in their stock prices.

Portfolio Pulse from Avi Kapoor

February 09, 2024 | 6:18 pm

In Friday's intraday session, several health care stocks experienced significant movements. Notably, Intelligent Bio Solutions (INBS) surged by 219.4%, while Synlogic (SYBX) dropped by 46.8%. Other companies like NanoString Technologies (NSTG), TC BioPharm (TCBP), and Arcutis Biotherapeutics (ARQT) also saw notable price changes. These movements reflect a dynamic day in the health care sector, with both substantial gains and losses.

Portfolio Pulse from Benzinga Insights

February 09, 2024 | 5:31 pm

In Friday's pre-market session, several healthcare stocks showed significant movement. NanoString Technologies, TC BioPharm, OKYO Pharma, Corvus Pharma, CytoMed Therapeutics, and Ontrak were among the gainers, with NanoString Technologies leading with a 26.9% increase. Conversely, Synlogic, BioXcel Therapeutics, Evoke Pharma, Syra Health, Inspire Veterinary, and Design Therapeutics were the losers, with Synlogic experiencing the largest drop of 52.2%.

Portfolio Pulse from Benzinga Insights

February 09, 2024 | 1:06 pm

Cloudflare, Inc. (NYSE:NET) shares surged over 25% in pre-market trading after reporting Q4 financial results that exceeded expectations and providing optimistic guidance for 2024. Other stocks also showed significant movement in pre-market trading, with notable gainers including Next.e.GO N.V. (NASDAQ:EGOX) and losers like Synlogic, Inc. (NASDAQ:SYBX).

Portfolio Pulse from Avi Kapoor

February 09, 2024 | 12:52 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.